TY - JOUR
T1 - Performance of the self-administered Psoriasis Area and Severity Index in evaluating clinical and sociodemographic subgroups of patients with psoriasis
AU - Sampogna, Francesca
AU - Sera, Francesco
AU - Mazzotti, Eva
AU - Pasquini, Paolo
AU - Picardi, Angelo
AU - Abeni, Damiano
AU - Alotto, Massimo
AU - Antonelli, Gianluca
AU - Bolli, Simone
AU - Cavalieri, Rino
AU - Chinni, Massimo Luca
AU - Fazio, Marcello
AU - Girolomoni, Giampiero
AU - Luchetti, Elisabetta
AU - Melchi, Carmelo Franco
AU - Salcedo, Nidia Melo
AU - Moscatelli, Paola
AU - Piazza, Paolo
AU - Picconi, Orietta
AU - Pilla, Maria Antonietta
AU - Primavera, Grazia
AU - Puddu, Pietro
AU - Ruatti, Paolo
AU - Ruggiero, Giuseppe
AU - Salvatori, Valentina
AU - Simoni, Romeo
AU - Sordi, Donatella
AU - Tiago, Albertina
PY - 2003/3/1
Y1 - 2003/3/1
N2 - Background: There is a need to evaluate severity of psoriasis with a simple, patient-assessed instrument. Objective: To investigate whether the self-administered Psoriasis Area and Severity Index (SAPASI) could be used as a measure of severity in different clinical types of psoriasis. Design: Hospital-based cross-sectional study, with measures of clinical severity collected separately by dermatologists (PASI) and patients with psoriasis (SAPASI). Setting: Part of a large project on clinical, epidemiological, emotional, and quality-of-life aspects of psoriasis (the IDI Multipurpose Psoriasis Research on Vital Experiences study), performed between February 21 and August 31, 2000, at the inpatient wards of the Istituto Dermopatico dell'Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy. Patients: The study population comprised 351 eligible patients with complete sets of information on PASI and SAPASI hospitalized at IDI-IRCCS with a diagnosis of psoriasis. Main Outcome Measures: Correlation between PASI and SAPASI scores and analysis of variance on the difference between PASI and SAPASI scores in subsets of patients based on clinical and sociodemographic characteristics. Results: A high correlation between the 2 measures was observed (overall Pearson correlation coefficient, r=0.69). The SAPASI values were higher and had a wider scattering than PASI values, and SAPASI was able to discriminate properly between clinical types and global severity as assessed by dermatologists. Conclusions: The SAPASI scoring system is well understood and accepted by patients in different populations than previously tested, adding confidence in the validity of the instrument. It could be used as a severity measure for psoriasis even for "at-distance" follow-up. Some caution, though, is needed when using SAPASI strictly to estimate PASI measurements, especially for guttate psoriasis.
AB - Background: There is a need to evaluate severity of psoriasis with a simple, patient-assessed instrument. Objective: To investigate whether the self-administered Psoriasis Area and Severity Index (SAPASI) could be used as a measure of severity in different clinical types of psoriasis. Design: Hospital-based cross-sectional study, with measures of clinical severity collected separately by dermatologists (PASI) and patients with psoriasis (SAPASI). Setting: Part of a large project on clinical, epidemiological, emotional, and quality-of-life aspects of psoriasis (the IDI Multipurpose Psoriasis Research on Vital Experiences study), performed between February 21 and August 31, 2000, at the inpatient wards of the Istituto Dermopatico dell'Immacolata-Istituto di Ricovero e Cura a Carattere Scientifico (IDI-IRCCS), Rome, Italy. Patients: The study population comprised 351 eligible patients with complete sets of information on PASI and SAPASI hospitalized at IDI-IRCCS with a diagnosis of psoriasis. Main Outcome Measures: Correlation between PASI and SAPASI scores and analysis of variance on the difference between PASI and SAPASI scores in subsets of patients based on clinical and sociodemographic characteristics. Results: A high correlation between the 2 measures was observed (overall Pearson correlation coefficient, r=0.69). The SAPASI values were higher and had a wider scattering than PASI values, and SAPASI was able to discriminate properly between clinical types and global severity as assessed by dermatologists. Conclusions: The SAPASI scoring system is well understood and accepted by patients in different populations than previously tested, adding confidence in the validity of the instrument. It could be used as a severity measure for psoriasis even for "at-distance" follow-up. Some caution, though, is needed when using SAPASI strictly to estimate PASI measurements, especially for guttate psoriasis.
UR - http://www.scopus.com/inward/record.url?scp=0037340952&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037340952&partnerID=8YFLogxK
U2 - 10.1001/archderm.139.3.353
DO - 10.1001/archderm.139.3.353
M3 - Article
C2 - 12622629
AN - SCOPUS:0037340952
SN - 0003-987X
VL - 139
SP - 353
EP - 358
JO - Archives of Dermatology
JF - Archives of Dermatology
IS - 3
ER -